TAK FY 2017 Earnings Report — Takeda Pharmaceutical Company Limited Revenue & Financial Results | Market Cap Arena

Takeda Pharmaceutical Company LimitedTAK

FY 2017 Earnings

Reported March 30, 2018

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2017	Prior Q	FY 2016	QoQ Change	YoY Change
Revenue	$11.1B	—	$10.9B	—	2.2%
Op. Income	$1.5B	—	$977M	—	55.1%
Gross Margin	72.0%	—	67.7%	—	4.2pp
Net Margin	10.6%	—	6.6%	—	3.9pp
EPS (Diluted)	$0.74	—	$0.46	—	62.4%
Free Cash Flow	$1.6B	—	$936M	—	67.1%

Revenue Flow

Item	Amount
REVENUE	$11.1B
Cost of Revenue	$3.1B
GROSS PROFIT	$8.0B
R&D Expenses	$2.0B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$3.9B
Other Expenses	$4.4B
Operating Expenses	$6.5B
Cost & Expenses	$9.6B
OPERATING INCOME	$1.5B
Interest Income	$248M
Interest Expense	$200M
Other Income/Expenses	-$154M
INCOME BEFORE TAX	$1.4B
Income Tax Expense	$191M
Net Income from Continuing Ops	$1.2B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$1.2B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$1.2B
D&A	$1.1B
EBIT	$1.4B
EBITDA	$2.3B
EPS	$1
EPS Diluted	$1

Income Statement

Item	Amount
REVENUE	$11.1B
Cost of Revenue	$3.1B
GROSS PROFIT	$8.0B
R&D Expenses	$2.0B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$3.9B
Other Expenses	$4.4B
Operating Expenses	$6.5B
Cost & Expenses	$9.6B
OPERATING INCOME	$1.5B
Interest Income	$248M
Interest Expense	$200M
Other Income/Expenses	-$154M
INCOME BEFORE TAX	$1.4B
Income Tax Expense	$191M
Net Income from Continuing Ops	$1.2B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$1.2B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$1.2B
D&A	$1.1B
EBIT	$1.4B
EBITDA	$2.3B
EPS	$1
EPS Diluted	$1

Cash Flow Statement

Item	Amount
Net Income	$1.2B
Depreciation & Amortization	$1.1B
Stock-Based Compensation	$117M
Deferred Income Tax	$191M
Other Non-Cash Items	-$335M
Change in Working Capital	$84M
OPERATING CASH FLOW	$2.4B
Capital Expenditure	-$804M
Acquisitions (Net)	$356M
Purchases of Investments	-$555M
Sales/Maturities of Investments	$255M
Other Investing Activities	$163M
NET CASH FROM INVESTING	-$585M
Net Debt Issuance	-$959M
Common Stock Repurchased	-$118M
Common Dividends Paid	-$889M
Other Financing Activities	-$78M
NET CASH FROM FINANCING	-$2.0B
FREE CASH FLOW	$1.6B
Net Change in Cash	-$293M

Balance Sheet

Item	Amount
Cash & Equivalents	$1.8B
Short-Term Investments	$505M
Net Receivables	$2.7B
Inventory	$1.3B
Other Current Assets	$388M
TOTAL CURRENT ASSETS	$6.8B
PP&E (Net)	$3.4B
Goodwill	$6.4B
Intangible Assets	$6.4B
Long-Term Investments	$1.9B
Tax Assets	$407M
Other Non-Current Assets	$489M
TOTAL NON-CURRENT ASSETS	$19.0B
TOTAL ASSETS	$25.7B
Account Payables	$838M
Short-Term Debt	$112.8K
Deferred Revenue	$0
Other Current Liabilities	$2.7B
TOTAL CURRENT LIABILITIES	$4.6B
Long-Term Debt	$6.2B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$568M
Other Non-Current Liabilities	$1.7B
TOTAL NON-CURRENT LIABILITIES	$8.5B
TOTAL LIABILITIES	$13.1B
Common Stock	$1.1B
Additional Paid-In Capital	$568M
Retained Earnings	$9.8B
Treasury Stock	-$466M
Accum. Other Comp. Income	-$30M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$12.5B
Minority Interest	$125M
TOTAL EQUITY	$12.6B
TOTAL LIABILITIES & EQUITY	$25.7B
Total Debt	$6.2B
Net Debt	$4.3B